| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
(20R)-Ginsenoside Rg3 inhibits the growth of human venous endothelial cells (HUVEC) with an IC50 of 10 nM[1]. In either the presence of a simulated variable dilution matrix with 20 ng/mL VEGF or without it, (20R)-ginsenoside Rg3 significantly exfoliated VEGF-induced HUVEC. In isolated microvessel sprouting and (20R)-ginsenoside Rg3 chemical sensing in arterial aortic ring tests [1]. HUVEC capillaries form on the gel in the arterial Matrigel plug experiment [1]. Angiogenesis caused by basic fibroblast growth factor (bFGF) is dramatically inhibited by (20R)-ginsenoside Rg3 at 150 and 600 nM [1].
|
|---|---|
| ln Vivo |
(20R)-Ginsenoside Rg3 (0.05-0.5 mg/kg; intranasal medicine; lasts for 2 weeks) has demonstrated anti-fatigue properties when administered as a spray [2].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HUVEC Tested Concentrations: 1 nM, 10 nM, 100 nM, 1000 nM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibited HUVEC proliferation. |
| Animal Protocol |
Animal/Disease Models: Male Kunming mice, body weight 18-22 g[2]
Doses: 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg (5 μL per nostril) Route of Administration: intranasal administration; 2 weeks Experimental Results: Weight-bearing swimming time was Dramatically prolonged, and liver glycogen levels were also increased. |
| References | |
| Additional Infomation |
(20S)-ginsenoside Rg3 is a ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. It has a role as an apoptosis inducer, an antineoplastic agent, a plant metabolite and an angiogenesis modulating agent. It is a ginsenoside, a tetracyclic triterpenoid and a glycoside. It is functionally related to a (20S)-protopanaxadiol. It derives from a hydride of a dammarane.
Ginsenoside Rg3 has been reported in Panax notoginseng, Panax ginseng, and other organisms with data available. |
| Molecular Formula |
C42H72O13
|
|---|---|
| Molecular Weight |
785.01328
|
| Exact Mass |
1078.592
|
| CAS # |
38243-03-7
|
| Related CAS # |
20(S)-Ginsenoside Rg3;14197-60-5
|
| PubChem CID |
9918693
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1117.1±65.0 °C at 760 mmHg
|
| Melting Point |
315-318ºC
|
| Flash Point |
629.4±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
4.73
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
55
|
| Complexity |
1370
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C
|
| InChi Key |
RWXIFXNRCLMQCD-JBVRGBGGSA-N
|
| InChi Code |
InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~53.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.17 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2739 mL | 6.3693 mL | 12.7387 mL | |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL | |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
